6132.HK climbed more than 6% during regular trading to HK$37.42.

The biotech firm, which first listed yesterday at HK$81.80, saw its shares plunge 56.9% on the initial session and close at HK$35.26, making it among this year's worst performing debuts.

The stock touched a record low of HK$32 before staging a recovery to a high of HK$43.02, registering an intraday range exceeding 34%.

Huajian Future is a clinical-stage biotechnology company specializing in small-molecule drug development. Its pipeline includes HJ787, HJ178, and HJ891, none yet approved for commercial sales.

The company reported 2025 revenue of approximately HK$12.98 million with a net loss of about HK$135 million. The IPO attracted oversubscription exceeding 2,000 times, though post-listing performance significantly missed expectations. Anchor investors Ruifeng Fund and Kaibo each committed US$25 million and now face floating losses exceeding tens of millions of dollars.